Share

AstraZeneca hit after drug linked to suicide fears

London - AstraZeneca's hopes of topping $45bn in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller.

Amgen, its partner on the project, announced late on Friday it was ending a collaboration to develop brodalumab after suicidal thoughts were observed in patients taking the medicine.

Shares in AstraZeneca fell 1% on Tuesday in the wake of the news, following a long holiday weekend in Britain.

Deutsche Bank analyst Richard Parkes said the setback was a surprise and terminating the drug's development would hit long-term consensus forecasts for AstraZeneca's earnings by around 2%.

Although the British group said it was still considering whether to scrap the product or continue on its own, the drug's prospects now seem badly tarnished with Amgen declaring that safety concerns would likely result in restricted use.

AstraZeneca and Amgen have been sharing development of brodalumab since 2012 as a treatment for psoriasis, psoriatic arthritis and axial spondyloarthritis. It works by blocking a molecule involved in inflammation called interleukin-17.

Novartis already markets a psoriasis drug called Cosentyx that binds to a related protein, IL-17A, without any problems involving suicidal thoughts, and Eli Lilly has a rival in development.

Barclays analysts said AstraZeneca might still decide to continue development on its own, but with the Novartis drug showing a clean bill of health and Eli Lilly aiming to submit its IL-17 for approval by mid-year "the commercial perspectives are clearly very challenging".

AstraZeneca gave its long-term $45bn sales forecast a year ago when it was fending off a takeover bid by Pfizer . It said at the time that estimates for annual brodalumab sales were between $500m and $1.5bn.

The company made $26bn of revenues last year.

We live in a world where facts and fiction get blurred
Who we choose to trust can have a profound impact on our lives. Join thousands of devoted South Africans who look to News24 to bring them news they can trust every day. As we celebrate 25 years, become a News24 subscriber as we strive to keep you informed, inspired and empowered.
Join News24 today
heading
description
username
Show Comments ()
Rand - Dollar
18.88
+0.3%
Rand - Pound
23.86
+0.2%
Rand - Euro
20.38
+0.3%
Rand - Aus dollar
12.32
+0.1%
Rand - Yen
0.12
+0.2%
Platinum
908.05
0.0%
Palladium
1,014.94
0.0%
Gold
2,232.75
-0.0%
Silver
24.95
-0.1%
Brent Crude
87.00
+1.8%
Top 40
68,346
0.0%
All Share
74,536
0.0%
Resource 10
57,251
0.0%
Industrial 25
103,936
0.0%
Financial 15
16,502
0.0%
All JSE data delayed by at least 15 minutes Iress logo
Company Snapshot
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE
Government tenders

Find public sector tender opportunities in South Africa here.

Government tenders
This portal provides access to information on all tenders made by all public sector organisations in all spheres of government.
Browse tenders